BRANFORD, Conn. February 02, 2018
ABCT, Connecticutâ€™s newest life science startup accelerator and a CTNext partner program, announced today the new cohort accepted to its 2018 cycle. The ABCT team has identified and invited 12 promising innovations and passionate scientific and technical minds to join the inaugural 2018 Class of the ABCT program and to accelerate the development of their technologies into successful businesses. Ventures technologies were developed at UConn, Yale, Quinnipiac, Weill Cornell, NYU and Columbia research institutions. All of the accepted startups have already received funding and are now seeking broader mentor networks for fundraising and team building.
The selected startups were chosen through an extensive screening process, which includes experts who rated ventures based on metrics including the strength of the team, uniqueness of insights into the problems they are solving, and their capacity to revolutionize the life science industry.
ABCT 2018 Cohort Ventures:
- AlloMek – A small molecule based therapeutics for rare diseases led by Uday Khire.
- B2D2 – A device to diagnose concussions led by Barry Kosofsky.
- CalRegen – A protein (bio-therapeutic) calreticulin, for tissue regeneration, led by Leslie Gold in affiliation with NYU.
- Cytosolix – A small-molecule tumor targeted chemotherapy platform, led by John Deacon in affiliation with Yale.
- Halo Gard (Vanessa Research) – A device to treat urinary incontinence in women, led by Ferenc Fazekas of Vanessa Research and Quinnipiac University.
- Irrashional – An antidote for poison ivy led by Madalina Ene.
- Lambda Vision – A protein-coated retinal implant led by Nicole Wagner of UConn Health Center
- LifestyleCX – A senior care personal matching service, led by Terri Sullivan.
- Mission Biomedical Scientific – A wearable monitoring device to monitor changes in metabolism on a continuous basis, led by Frank Swenson.
- Orthomedix – A device to address the unmet implant fixation and infection control needs of the orthopedic surgeon, led by Jim Walls.
- Shoreline Biome – A Microbiome assay and analysis software, led by Thomas Jarvie.
- Vesselon – A drug delivery platform led by Rhodemann Li.
ABCT is a competitive entry, 6-month long program that helps emerging bioscience ventures grow by providing entrepreneurship education and business networking to access global funders and prospective team members. ABCT aims to support the development of Connecticut as a hub of bioscience invention and commercialization by harnessing the creativity and ambition present in the stateâ€™s academic institutions, spinouts from established institutions and serial entrepreneurs and connect this talent with the scientific experts and business leaders in CT, NYC, and globally. ABCT supports young entrepreneurs by providing them with the education and networks critical to start successful bioscience based businesses. Local and global corporations are supporting the ABCT program including Purdue Pharma, Pfizer, Microsoft, Kaneka and Shipman and Goodwin. For more information see ABCT.com
About Design Technologies
Design Technologies helps build emergent IP focused ventures and founded ELabNYC, the successful biosciences pre-accelerator program in NYC for research institution spin outs. ELabNYC is currently working with its 6th program cohort. ELabNYCâ€™s 95 alumni ventures raised $45M during the program and $190M subsequent to graduation, including Landos – $10M closed with Perceptive/Xontogeny in September 2017.
Latest posts by Maria Burns (see all)
- Dubai Moves to Honour Knowledge Pioneer With $1 Million Mohammed bin Rashid Al Maktoum Knowledge Award - May 20, 2018
- Court Dismisses Andrea Tantaros Lawsuit Against Fox News And Pete Snyder - May 20, 2018
- President Jimmy Carter spurs Liberty University Class of 2018 to success through service - May 19, 2018